StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) stock

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Fennec Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Fennec Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was -$2.04M. For fiscal 2025 it was -$12.47M, down 146.2% from the year before. The highest annual figure on record is $26.98M in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$12.47M-146.2%
FY2024Dec 31, 2024$26.98M–
FY2023Dec 31, 2023-$17.14M–
FY2022Dec 31, 2022-$18.06M–
FY2021Dec 31, 2021-$14.22M–
FY2020Dec 31, 2020-$15.60M–
FY2019Dec 31, 2019-$9.06M–
FY2018Dec 31, 2018-$7.83M–
FY2017Dec 31, 2017-$3.64M–
FY2016Dec 31, 2016-$2.12M–
FY2015Dec 31, 2015-$1.86M–
FY2014Dec 31, 2014-$1.70M–
FY2013Dec 31, 2013-$2.21M–
FY2012Dec 31, 2012-$2.99M–
FY2011Dec 31, 2011-$3.23M–
FY2010Dec 31, 2010-$1.93M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$50.00K–
Q1 FY2026Mar 31, 2026$2.38M–
Q4 FY2025Dec 31, 2025-$5.96M–
Q3 FY2025Sep 30, 2025$1.49M–
Q2 FY2025Jun 30, 2025-$3.69M–
Q1 FY2025Mar 31, 2025-$4.32M-111.1%
Q4 FY2024Dec 31, 2024-$1.47M–
Q3 FY2024Sep 30, 2024-$2.21M–
Q2 FY2024Jun 30, 2024-$8.39M–
Q1 FY2024Mar 31, 2024$39.05M–
Q4 FY2023Dec 31, 2023-$4.86M–
Q3 FY2023Sep 30, 2023-$2.76M–
Q2 FY2023Jun 30, 2023-$3.95M–
Q1 FY2023Mar 31, 2023-$5.58M–
Q4 FY2022Dec 31, 2022-$6.80M–
Q3 FY2022Sep 30, 2022-$5.01M–
Q2 FY2022Jun 30, 2022-$3.39M–
Q1 FY2022Mar 31, 2022-$2.86M–
Q4 FY2021Dec 31, 2021-$3.25M–
Q3 FY2021Sep 30, 2021-$2.96M–
Q2 FY2021Jun 30, 2021-$4.43M–
Q1 FY2021Mar 31, 2021-$3.59M–
Q4 FY2020Dec 31, 2020-$3.28M–
Q3 FY2020Sep 30, 2020-$5.45M–
Q2 FY2020Jun 30, 2020-$3.12M–
Q1 FY2020Mar 31, 2020-$3.75M–
Q4 FY2019Dec 31, 2019-$1.59M–
Q3 FY2019Sep 30, 2019-$2.24M–
Q2 FY2019Jun 30, 2019-$2.76M–
Q1 FY2019Mar 31, 2019-$2.48M–
Q4 FY2018Dec 31, 2018-$2.93M–
Q3 FY2018Sep 30, 2018-$1.60M–
Q2 FY2018Jun 30, 2018-$1.57M–
Q1 FY2018Mar 31, 2018-$1.73M–
Q4 FY2017Dec 31, 2017-$1.32M–
Q3 FY2017Sep 30, 2017-$958.00K–
Q2 FY2017Jun 30, 2017-$688.00K–
Q1 FY2017Mar 31, 2017-$675.00K–
Q4 FY2016Dec 31, 2016-$611.00K–
Q3 FY2016Sep 30, 2016-$544.00K–

More Fennec Pharmaceuticals figures

See a number that looks wrong?